adociaquinone A | 113830-99-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: adociaquinone A
• 英文别名: 1-Methyl-10,10-dioxo-18-oxa-10lambda6-thia-7-azahexacyclo[15.6.1.02,15.04,13.06,11.020,24]tetracosa-2(15),3,6(11),13,17(24),19-hexaene-5,12,16-trione；1-methyl-10,10-dioxo-18-oxa-10λ6-thia-7-azahexacyclo[15.6.1.02,15.04,13.06,11.020,24]tetracosa-2(15),3,6(11),13,17(24),19-hexaene-5,12,16-trione
• CAS: 113830-99-2
• 化学式: C₂₂H₁₇NO₆S
• 分子量: 423.446
• InChiKey: BOWXVFKIAWTBOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  亚牛磺酸 、 (+/-)-xestoquinone 以 乙醇 、 乙腈 为溶剂， 反应 0.02h， 以14 mg的产率得到adociaquinone B
  参考文献：
  名称：

  Xesto- and halenaquinone derivatives from a sponge, Adocia sp., from Truk lagoon

  摘要：

  DOI：

  10.1021/jo00252a007

文献信息

• Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：EP2130826A1

  公开（公告）日：2009-12-09

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cancer. IDO inhibitors of this invention are homologs of annulin A, annulin B or annulin C.

  本研究提供了吲哚胺 2,3-二氧化酶（IDO）的抑制剂以及含有此类抑制剂的药物组合物，还提供了使用此类抑制剂和组合物治疗哺乳动物体内以 IDO 介导的色氨酸代谢途径病理学为特征的疾病的方法。此类病症可能涉及抑制 T 细胞介导的免疫反应，也可能直接导致色氨酸耗竭或色氨酸降解产物的积累。具体的疾病情况包括癌症。本发明的 IDO 抑制剂是鹅膏素 A、鹅膏素 B 或鹅膏素 C 的同源物。
• Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
  申请人：ANDERSEN Raymond J.

  公开号：US20090042868A1

  公开（公告）日：2009-02-12

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.
• INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS
  申请人：Chen Wei

  公开号：US20090155311A1

  公开（公告）日：2009-06-18

  The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.
• US7799776B2
  申请人：——

  公开号：US7799776B2

  公开（公告）日：2010-09-21
• Xesto- and halenaquinone derivatives from a sponge, Adocia sp., from Truk lagoon
  作者：Francis J. Schmitz、Stephen J. Bloor

  DOI：10.1021/jo00252a007

  日期：1988.8